A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis

Alonso López, S; Devesa Medina, María José; Izquierdo Rubio, Sonia; Rincón Rodríguez, Diego; Bañares Cañizares, Rafael

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis

Download

paper_CHC.pdf (243.32 KB)

Official URL

https://journals.lww.com/hep/abstract/2020/12000/a_model_based_on_noninvasive_markers_predicts_very.9.aspx

Publication date

2020

Authors

Alonso López, S

Devesa Medina, María José

Izquierdo Rubio, Sonia

Rincón Rodríguez, Diego

Bañares Cañizares, Rafael

Publisher

Lippincott, Williams & Wilkins

Citations

Exportar

URI

https://hdl.handle.net/20.500.14352/98654

Citation

Alonso López S, Manzano ML, Gea F, Gutiérrez ML, Ahumada AM, Devesa MJ, Olveira A, Polo BA, Márquez L, Fernández I, Cobo JCR, Rayón L, Riado D, Izquierdo S, Usón C, Real Y, Rincón D, Fernández-Rodríguez CM, Bañares R. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis. Hepatology. 2020 Dec;72(6):1924-1934. doi: 10.1002/hep.31588. Epub 2020 Nov 10. PMID: 33022803.

Abstract

virus (HCV) and advanced fibrosis remain at risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need lifelong surveillance. Because HCC risk is not homogenous and may decrease with fibrosis regression, we aimed to identify patients with low HCC risk based on the prediction of noninvasive markers and its changes after SVR. APP ROA CH AND RESULT S: This is a multicenter cohort study, including patients with HCV and compensated advanced fibrosis that achieved SVR after direct antivirals. Clinical and transient elastography (TE) data were registered at baseline, 1 year, and 3 years after the end of treatment (EOT). All patients underwent liver ultrasound scan every 6 months. Patients with clinical evaluation 1 year after EOT were eligible. Univariate and multivariate Cox regression analysis were performed, and predictive models were constructed. HCC occurrence rates were evaluated by Kaplan-Meier. Nine hundred and ninety-three patients were eligible (56% male; 44% female; median age 62 years), 35 developed HCC (3.9%), and the median follow-up was 45 months (range 13-53). Baseline liver stiffness measurement (LSM) (HR 1.040; 95% CI 1.017-1.064), serum albumin (HR 0.400; 95% CI 0.174- 0.923), 1-year DeltaLSM (HR 0.993; 95% CI 0.987-0.998), and 1-year FIB-4 score (HR 1.095; 95% CI 1.046-1.146) were independent factors associated with HCC. The TE-based HCC risk model predicted 0% of HCC occurrence at 3 years in patients with score 0 (baseline LSM ≤ 17.3 kPa, albumin >4.2 g/dL, and 1-year DeltaLSM > 25.5%) versus 5.2% in patients with score 1-3 (Harrell’s C 0.779; log-rank 0.002). An alternative model with FIB-4 similarly predicted HCC risk. CONCLUSIONS: A combination of baseline and dynamic changes in noninvasive markers may help to identify patients with a very low risk of HCC development after SVR.

Description

En este estudio se describe un modelo de predicción del riesgo de desarrollar hepatocarcinoma en pacientes con enfermedad hepática avanzada por virus C tras alcanzar la curación virológica. Se demuestra en el estudio que variables de fácil obtención (FIB-4, elastografía) que evalúan el grado de rigidez hepática y su dinámica influyen en el riesgo de desarrollar cáncer hepático. Se trata de un estudio multicéntrico coordinado desde el grupo del solicitante que pretende responder a una pregunta clave con claras connotaciones relacionadas con la práctica clínica. Además de su publicación en una revista de primer decil, este artículo ha supuesto el desarrollo de una colaboración multinacional que ha dado lugar a diversoss artículos posteriores.